Park Avenue Securities’s Bristol-Myers Squibb BMY Stock Holding History

Park Avenue Securities’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.21M	Sell	73,042 -4,051	-5%	-$233K	0.03%	427
2026 Q1	$4.68M	Buy	77,093 +18,508	+32%	+$1.08M	0.04%	329
2025 Q4	$3.16M	Buy	58,585 +4,754	+9%	+$229K	0.03%	405
2025 Q3	$2.43M	Buy	53,831 +17,266	+47%	+$806K	0.02%	516
2025 Q2	$1.69M	Sell	36,565 -30,214	-45%	-$1.48M	0.02%	579
2025 Q1	$4.07M	Buy	66,779 +9,973	+18%	+$581K	0.05%	234
2024 Q4	$3.21M	Buy	56,806 +13,952	+33%	+$780K	0.03%	334
2024 Q3	$2.22M	Sell	42,854 -1,589	-4%	-$74.5K	0.02%	406
2024 Q2	$1.85M	Sell	44,443 -8,068	-15%	-$361K	0.02%	437
2024 Q1	$2.85M	Buy	52,511 +12,363	+31%	+$630K	0.04%	303
2023 Q4	$2.06M	Sell	40,148 -10,652	-21%	-$559K	0.03%	370
2023 Q3	$2.95M	Buy	50,800 +1,063	+2%	+$65.1K	0.05%	242
2023 Q2	$3.18M	Sell	49,737 -6,200	-11%	-$416K	0.05%	226
2023 Q1	$3.88M	Buy	55,937 +10,343	+23%	+$730K	0.07%	184
2022 Q4	$3.28M	Buy	45,594 +8,729	+24%	+$658K	0.06%	202
2022 Q3	$2.62M	Buy	36,865 +2,273	+7%	+$165K	0.05%	211
2022 Q2	$2.66M	Buy	34,592 +1,506	+5%	+$115K	0.05%	216
2022 Q1	$2.42M	Buy	33,086 +13,078	+65%	+$878K	0.04%	238
2021 Q4	$1.25M	Buy	20,008 +3,315	+20%	+$194K	0.02%	386
2021 Q3	$988K	Sell	16,693 -6,468	-28%	-$426K	0.02%	416
2021 Q2	$1.55M	Sell	23,161 -7,624	-25%	-$497K	0.03%	272
2021 Q1	$1.94M	Sell	30,785 -3,625	-11%	-$226K	0.05%	203
2020 Q4	$2.13M	Buy	34,410 +1,600	+5%	+$98.4K	0.06%	148
2020 Q3	$1.98M	Buy	32,810 +2,262	+7%	+$136K	0.07%	137
2020 Q2	$1.8M	Buy	+30,548	New	+$1.83M	0.07%	129
2020 Q1	–	Sell	-17,666	Closed	-$1.13M	–	328
2019 Q4	$1.13M	Buy	17,666 +4,359	+33%	+$250K	0.05%	159
2019 Q3	$675K	Buy	+13,307	New	+$625K	0.03%	207
2019 Q2	–	Sell	-10,408	Closed	-$490K	–	276
2019 Q1	$490K	Buy	+10,408	New	+$518K	0.03%	227
2016 Q3	–	Sell	-3,298	Closed	-$243K	–	48
2016 Q2	$243K	Buy	+3,298	New	+$233K	0.04%	72

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Park Avenue Securities's BMY Position: Q2 2026 in Review

Park Avenue Securities reduced its Bristol-Myers Squibb (BMY) stake by 5.3% in Q2 2026, selling an estimated $233K and leaving 73,042 shares worth $4.21M. The position accounts for 0.03% of the portfolio, ranked #427.

Park Avenue Securities first reported a position in BMY in Q2 2016 and has held it in 29 quarters since. The position peaked at $4.68M in Q1 2026. 831 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Park Avenue Securities held 73,042 shares of Bristol-Myers Squibb worth $4.21M as of Q2 2026.
Park Avenue Securities sold 4,051 Bristol-Myers Squibb shares in Q2 2026, an estimated $233K.
Bristol-Myers Squibb made up 0.03% of Park Avenue Securities's portfolio in Q2 2026, its #427 holding.
Park Avenue Securities first reported a position in Bristol-Myers Squibb in Q2 2016 and has held it in 29 quarters since.
Park Avenue Securities's Bristol-Myers Squibb position peaked at $4.68M in Q1 2026.
831 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.